NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases

The CEO used personal funds for the purchases, and NeOnc issued no shares in connection with the transactions.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) announced that CEO Amir F. Heshmatpour purchased 80,000 shares on the open market on November 5, 6 and 9, 2026. The purchases totaled $269,082, at a weighted average of approximately $3.36 per share. He used personal funds; NeOnc issued no shares. His 2026 open-market purchases total 271,000 shares for approximately $1.11 million.

In the single-arm Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, six-month progression-free survival was 48.9% against a prespecified 20% benchmark (p = 0.0047). Median overall survival was 26.1 months. NEO212 completed Phase 1 dose escalation and established a recommended Phase 2 dose. Both programs have data presentations scheduled for November 13. An October memorandum of understanding with the Department of Health – Abu Dhabi covers advancing brain cancer research and exploring clinical trial opportunities, including pediatric oncology.

5 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointNEO100 six-month progression-free survival was 48.9% versus a prespecified 20% benchmark in the single-arm Phase 2a study (p = 0.0047).
• Moderate point. Forward-looking: it has not happened yet and may not happen.Abu Dhabi research agreement aims to advance brain cancer research and explore clinical trial opportunities, including pediatric oncology.
• Minor pointCEO open-market purchases reached 271,000 shares for approximately $1.11 million in 2026.
• Minor pointNEO100 median overall survival was 26.1 months in the recurrent IDH1-mutant high-grade glioma study.
• Minor pointNEO212 completed Phase 1 dose escalation and established a recommended Phase 2 dose.

Negative

• Minor pointAbu Dhabi collaboration remains a memorandum of understanding, with clinical trial opportunities still to be explored.

Argus 15 min delay 26 alerts

+13.64% vs previous close $4.25 last price 4.2x rel. volume Open Argus

Details

Market move: NTHI +13.64% vs previous close. insider share purchases

+19.4% Peak in 53 min

$3.71 – $4.67 Day Range

$122.61M Mkt Cap at Last Price

On Nov 10, the day this news came out, the latest delayed price for NTHI is 13.64% above the previous close. Argus tracked a peak move of +19.4% during the session. Our momentum scanner has recorded 26 alerts for this stock so far that day. The latest delayed price is $4.25. Relative volume is very high at 4.2x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Shares purchased: 80,000 shares Purchase total: $269,082 2026 accumulated purchases: 271,000 shares +2 more

Shares purchased

80,000 shares

Open-market purchases on November 5, 6 and 9, 2026

Purchase total

$269,082

Based on reported prices for the 80,000-share purchases

2026 accumulated purchases

271,000 shares

Open-market purchases across April, May, August, September and November

Six-month progression-free survival

48.9% vs. 20% benchmark; p=0.0047

Single-arm Phase 2a study of intranasal NEO100

Median overall survival

26.1 months

Intranasal NEO100 Phase 2a study

Key Terms

sec form 4, single-arm, phase 2a, progression-free survival

4 terms

sec form 4 regulatory

"based on his SEC Form 4 filings"

A SEC Form 4 is a U.S. Securities and Exchange Commission filing that insiders must use to report changes in their beneficial ownership of a company’s equity securities—typically officers, directors, and owners of more than 10%—under Section 16 of the Securities Exchange Act of 1934. It lists the date, type of transaction (purchase, sale, grant, exercise, derivative transaction), number of shares or units, price and resulting ownership, and must generally be filed electronically within two business days of the transaction; it complements Form 3 (initial holdings) and Form 5 (annual or late transactions). The form exists to provide near‑real‑time public disclosure of insider transactions and is submitted through the SEC’s EDGAR system, with specific reporting rules and exceptions prescribed by the Exchange Act and SEC regulations.

single-arm medical

"In the single-arm Phase 2a study"

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

phase 2a medical

"single-arm Phase 2a study of intranasal NEO100"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

progression-free survival medical

"six-month progression-free survival was 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

2026 open-market purchases total 271,000 shares for approximately $1.11 million

CALABASAS, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced that Amir F. Heshmatpour, its Executive Chairman, President and Chief Executive Officer, purchased 80,000 shares of NeOnc common stock on the open market on November 5, 6 and 9, 2026. The purchases totaled $269,082 based on reported prices, at a weighted average of approximately $3.36 per share. Heshmatpour used personal funds, and the Company issued no shares in connection with the transactions.

Heshmatpour has accumulated 271,000 shares through open-market purchases across April, May, August, September and November 2026, based on his SEC Form 4 filings and the brokerage confirmation for his November 9 purchase. He purchased 191,000 of those shares for approximately $688,000 following NeOnc’s August 12 announcement of topline Phase 2a results for intranasal NEO100.

“I’ve invested more than $1 million of my own money in NeOnc shares this year,” said Heshmatpour. “I’ve added to my position repeatedly because I believe in the long-term potential of NEO100 and NEO212 for patients with brain cancer. These purchases deepen my personal investment alongside our shareholders.”

In the single-arm Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, six-month progression-free survival was 48.9% against a prespecified 20% benchmark (p = 0.0047). Median overall survival was 26.1 months. NEO212 has completed Phase 1 dose escalation and established a recommended Phase 2 dose. NeOnc is scheduled to present data from both programs at the Society for Neuro-Oncology Annual Meeting on November 13. In October, NeOnc signed a memorandum of understanding with the Department of Health – Abu Dhabi to advance brain cancer research and explore clinical trial opportunities in the emirate, including in pediatric oncology.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s clinical development programs, the clinical potential of NEO100 and NEO212, and the presentation of data at the Society for Neuro-Oncology Annual Meeting. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. NEO212 is also investigational and has not been approved by any regulatory authority. The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

Company Contact:
info@neonc.com

Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026

This press release was published by a CLEAR® Verified individual.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NeOnc shares did CEO Amir Heshmatpour buy in November 2026?

Heshmatpour purchased 80,000 shares on November 5, 6 and 9, 2026, for $269,082 based on reported prices. The weighted average was approximately $3.36 per share. He used personal funds, and NeOnc issued no shares in connection with the transactions.

How much NeOnc stock did Heshmatpour buy after the NEO100 Phase 2a results announcement?

Heshmatpour purchased 191,000 shares for approximately $688,000 following NeOnc’s August 12 announcement of topline Phase 2a results for intranasal NEO100.